New institutional accounts ordering LYMPHIR increased 78% quarter over quarterLYMPHIR's near-uni

New institutional accounts ordering LYMPHIR increased 78% quarter over quarter LYMPHIR's near-univer

Citius Oncology, Inc. (NASDAQ: CTOR - Get Free Report)'s share price rose 0.6% during mid-day tradin

Expanded commercial and medical affairs teams expected to be fully operational throughout the U.S. b

Expanded commercial and medical affairs teams expected to be fully operational throughout the U.S. b

Gainers Seer (NASDAQ:SEER) shares rose 32.1% to $2.14 during Monday's pre-market session. The m

Gainers Universe Pharmaceuticals (NASDAQ:UPC) stock moved upwards by 168.2% to $7.94 during Friday&

Citius Oncology, Inc. ("Citius Oncology") (NASDAQ:CTOR), an oncology‑focused biopharmaceutic

Investigator-initiated study data presented May 30, 2026, at the American Society of Clinical Oncolo

24% Objective Response Rate, with an average of 21.1 month Duration of Response in responders, and f

$5.6 million in net revenue for the first half of fiscal 2026 as LYMPHIR ® launch progresses Up to $

$5.6 Million in net revenue for the first half of fiscal 2026 from ongoing launch of LYMPHIR ® Citiu

Avenue Capital Group to provide up to $25 Million via Senior Credit Facility with an initial $10 mil

Order fulfilment expands international patient access to LYMPHIR following initial U.S. launch Distr

Broad institutional uptake among leading cancer centers and payer coverage supports early prescribin

Broad institutional uptake among leading cancer centers and payer coverage supports early prescribin

Citius Oncology to meet with cutaneous T-cell lymphoma (CTCL) specialists as part of ongoing clinica

Citius Oncology, Inc. ("Citius Oncology") (NASDAQ:CTOR), an oncology‑focused biopharmaceutic

Study data from patients with relapsed or refractory gynecologic cancers signals the potential of LY

Topline data of investigator‑initiated study at the University of Minnesota and City of Hope demonst

Topline data of investigator‑initiated study at the University of Minnesota and City of Hope demonst

Citius Oncology (NASDAQ:CTOR) reported quarterly losses of $(0.06) per share which missed the analys

Company reports $3.9 million in revenue generated from initial sales in December 2025 and provides f

Company reports $3.9 million in revenue generated from initial sales in December 2025 and provides f

Third international distribution agreement further advances global access strategy with major market

NEW YORK, Jan. 5, 2026 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Ci

Citius Pharmaceuticals shares jumped 22.12% after hours following the commercial launch of its LYMPH

Guru Stock PicksThird Avenue Value Fund has made the following transactions:Reduce in XTER: BMW by 5

Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (NASDAQ: CTXR), a bi

Cancer Immunotherapy, LYMPHIR™, launched in the U.S. in December 2025 Completed $36 million in strat

Subsidiary, Citius Oncology, launches cancer immunotherapy, LYMPHIR™, in the U.S. in December 2025 C

Citius Oncology, Inc. ("Citius Oncology") (NASDAQ:CTOR), the oncology-focused subsidiary of

Leading edge artificial intelligence and machine learning platform supports enhanced salesforce targ

McKesson joins leading distribution service providers as authorized U.S. distributor of LYMPHIRCRANF

EVERSANA to provide integrated commercialization services, enhancing launch readiness and market ent

Citius Oncology, Inc. ("Citius Oncology") (NASDAQ:CTOR), the oncology-focused subsidiary of

Proprietary model informs targeted sales and marketing strategies with feedback loop thataugments pr

Citius Oncology, Inc. ("Citius Oncology" or the "Company") (NASDAQ:CTOR), a majority

Agreement with global pharmaceutical solutions provider enhances commercial infrastructure and reinf